GPT and metabolic syndrome: Distinctive biomarker changes, including elevated liver enzymes [e.g., alanine aminotransferase (ALT) and aspartate aminotransferase (AST)] and dyslipidemia [e.g., heightened triglyceride (TG)], have been documented in GDM patients (13–16).